MDWDHealthcare · BiotechnologyThe 6 Wall Street analysts covering MediWound Ltd. hold a median 12-month price target of $30 — +111.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 3 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores MediWound Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (96): The share price has been relatively steady.
Quality (22): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MDWD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +111.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Oppenheimer | Maintains | Outperform | $32 → $30 |
| 28 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $36 |
| 28 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 May 2026 | Oppenheimer | Maintains | Outperform | $33 → $32 |
| 28 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 21 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2025 | Craig-Hallum | Initiates | Buy | — |
| 10 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Jan 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Sept 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MDWD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, MediWound Ltd. returned −20.7% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 10% of US stocks
Cheaper than 19% of US stocks
Cheaper than 80% of US stocks
Higher than 6% of US stocks
Higher than 12% of US stocks
Higher than 10% of US stocks
Higher than 9% of US stocks
Higher than 3% of US stocks
Higher than 17% of US stocks
Higher than 15% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MediWound Ltd. has a market value of $173.5M and an enterprise value of $147.6M.
Revenue in the twelve months to 30 June 2026: $11.9M. The latest quarter shrank 45.8% year on year.
Net income over the same four quarters: −$20.2M, a −170.1% net margin.
Diluted earnings per share, trailing twelve months: $−1.80.
Free cash flow in the twelve months to 30 June 2026: −$28.5M.
Trailing P/E: −6.4×; forward P/E: −5.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MediWound Ltd. employs 121 people — $98K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MediWound Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MediWound announced that it entered into an underwriting agreement with H.C. for a $15 million bought deal offering of ordinary shares.
Why it matters — The offering is a corporate financing update that MDWD watchers may want to track.
MediWound said it will report third-quarter 2026 financial results. A conference call and webcast are scheduled for Thursday, November 12, at 8:30 a.m. Eastern Time.
Why it matters — MDWD watchers can note the scheduled date and time for the company's results announcement and related call.
MediWound received an additional $3.3 million from the U.S. Department of War to advance work on a room-temperature-stable formulation of NexoBrid. This funding supports ongoing development of the product.
Why it matters — Additional government funding signals continued official support and progress toward a more convenient formulation of MediWound's flagship product, NexoBrid.
MediWound announced that the independent Data and Safety Monitoring Board (DSMB) completed its pre-specified periodic safety review of the ongoing Phase III VALUE study of EscharEx in patients with venous leg ulcers and recommended that the study continue without modification, with no safety concerns identified. Interim assessment and enrollment completion remain on track for the end of the first quarter of 2027.
Why it matters — For MDWD watchers, a clean DSMB safety review and on-track timeline for the pivotal Phase III VALUE study represent a positive clinical development milestone for the EscharEx program.
MediWound Ltd. announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made from the company's headquarters in Yavne, Israel.
Why it matters — An MDWD watcher would care because presenting at a major investment conference gives the company a platform to communicate with investors and the broader financial community.
The 6 Wall Street analysts covering MediWound Ltd. have a median 12-month price target of $30, with estimates ranging from $25 to $36. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering MediWound Ltd., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MediWound Ltd. 33 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, MediWound Ltd. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +111.4% from the last close, and Ticker Nerd's factor model ranks MediWound Ltd. 33 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MediWound Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDWD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $36 over the next 12 months.
MediWound Ltd. returned -20.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
MediWound Ltd. is a biopharmaceutical company focused on next-generation enzymatic therapies for non-surgical tissue repair.
The most recent item we track (GlobeNewsWire, 3 Nov 2026): "MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares". MediWound announced that it entered into an underwriting agreement with H.C. for a $15 million bought deal offering of ordinary shares.
MediWound Ltd. is a biopharmaceutical company focused on next-generation enzymatic therapies for non-surgical tissue repair. MediWound develops, manufactures, and commercializes products designed to address severe burns, chronic wounds, and other hard-to-heal tissue injuries. Its portfolio centers on biologic and protein-based treatments that selectively remove damaged tissue while preserving healthy tissue, supporting cleaner wound bed preparation and recovery care. The company serves hospitals, burn centers, and other healthcare providers involved in acute and specialized wound management. MediWound also works across tissue regeneration and related therapeutic areas, positioning itself within the broader wound care and regenerative medicine market. Headquartered in Yavne, Israel, MediWound emphasizes advanced, clinically focused solutions that aim to improve treatment workflows in modern wound care settings.
121 employees · Israel · https://www.mediwound.com
